Provate

Serious Warnings

• Black Box Warning: While betamethasone dipropionate topical does not carry a formal FDA Black Box Warning, it is imperative to include a 'Serious Warnings' section emphasizing the significant risks associated with its use, particularly given its high potency. **Serious Warnings: Adrenal Suppression and Systemic Effects.** Prolonged use, application to large surface areas, use under occlusive dressings, or application to areas with compromised skin barrier function can lead to significant systemic absorption of betamethasone dipropionate. This systemic absorption can result in hypothalamic-pituitary-adrenal (HPA) axis suppression, potentially leading to adrenal insufficiency upon abrupt discontinuation. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria have also been reported. Pediatric patients are at a significantly higher risk for systemic toxicity due to their larger skin surface area to body weight ratio and underdeveloped skin barrier. Regular monitoring for signs of HPA axis suppression (e.g., morning plasma cortisol, ACTH stimulation test) is crucial, especially in high-risk patients. Discontinue treatment if HPA axis suppression is suspected or confirmed, and implement a plan for gradual withdrawal if necessary to avoid adrenal crisis. Patients should be educated on the signs and symptoms of systemic corticosteroid effects and advised to seek immediate medical attention if they occur. Avoid use on the face, groin, or axillae for prolonged periods, and do not use for diaper dermatitis.
• Topical betamethasone dipropionate should be used with caution due to the potential for systemic absorption, which can lead to reversible HPA axis suppression, particularly with prolonged use, application over large body surface areas, or under occlusive dressings.
• Pediatric patients are more susceptible to systemic toxicity due to their greater skin surface area-to-body mass ratio.
• Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can occur.
• Treatment should be discontinued if HPA axis suppression is noted, and patients may require evaluation for adrenal insufficiency.
• The medication should not be used for ophthalmic purposes.
• It should be used judiciously in areas such as the face, groin, or axillae, and for diaper dermatitis, as these areas are more prone to adverse reactions including skin atrophy.
• If irritation or sensitization develops, treatment should be discontinued, and appropriate therapy instituted.
• Concomitant skin infections require appropriate antimicrobial therapy; if the infection does not respond, betamethasone dipropionate should be discontinued until the infection is adequately controlled.
• Pregnancy Category C; use only if the potential benefit justifies the potential risk to the fetus.